Executive Director, Business Development, RDU

Joining Alexion, AstraZeneca, Rare Disease, means embracing an opportunity where work isn’t ordinary, in a company where 'Here it means more' is more than a statement, it’s an ethos. We are a beacon in the global BioPharmaceutical landscape. Our closeness to patients brings us closer to our work and closer to each other. Combined with our brave, pioneering spirit – we are truly unique in R&D and healthcare.

The Executive Director, Business Development is a senior leader who will elevate the level of play across the BD team and will be accountable for sophisticated transactions from sourcing through due diligence, negotiation, and close.  This will include mentoring team members, leading partner engagement and projects, and building new relationships across the globe and representing Alexion at various meetings and conferences.   

Reporting to the Vice President, Business Development, this role is essential for ensuring the acceleration of innovative medicines to patients globally and improving the value of Alexion’s portfolio through inorganic growth strategies.  You will align deal terms to key risks and value inflections and structure multiple agreement types, including acquisitions, in-licensing, out-licensing, and collaborations.   

You will be responsible for: 

• Identifying opportunities by:  reviewing scientific and industry publications; networking, attending medical/scientific meetings, banking, and partnering conferences; and maintaining relationships with world-class investors and VCs 

• Ensuring efficient triaging and evaluation of new opportunities leading to recommendations and prioritization of only the highest quality opportunities 

• Ensuring priority BD opportunities are progressed efficiently to appropriate conclusion or deal execution, including:  structuring deal terms around key risks/ value inflections; business case development; financial modeling; and contract negotiations 

• Leading cross-functional teams through meticulous, but right-sized evaluation and due diligence, including:  Clinical, Research, Commercial, Regulatory, Finance, Legal, and Manufacturing 

• Driving well-informed decision making with “executive-ready” deliverables presented at appropriate governance forums  

• Giving to and adjusting the overall BD strategy to meet corporate objectives 

• Collaborate and engage with colleagues in broader AstraZeneca teams, as appropriate for the deal type and stage, including AstraZeneca Oncology, AstraZeneca Biopharmaceuticals, BDO, Corporate Development, Corporate Ventures, and Deal Finance 

• Engage anticipated post-close partners (e.g.,